产品
编 号：F157372
分子式：C9H12N2S
分子量：180.27
分子式：C9H12N2S
分子量：180.27
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
100mg
357
In-stock
500mg
521
In-stock
结构图
CAS No: 14222-60-7
产品详情
生物活性：
Protionamide (or prothionamide) is a drug used in the treatment of tuberculosis; has also been tested for use in the treatment of leprosy.Target: Anti tuberculosisAlthough ETH and PTH are both potent drugs against M. tuberculosis (MIC = ～0.5 μg/ml) (24), they do not affect E. coli growth, even at very high concentrations (100 μg/ml), which is primarily caused by the absence of an EthA homologue in E. coli . Clinical improvement was noted in 74% of the patients treated with ethionamide and in 83% of those treated with prothionamide. Therapy was well tolerated and drug-related hepatotoxicity did not require discontinuation of therapy. The 500-mg dose of both ethionamide and prothionamide resulted in loss in Mycobacterium leprae viability more rapidly than did the 250-mg dose, and prothionamide at both dose levels was superior to the equivalent dose of ethionamide .
Protionamide (or prothionamide) is a drug used in the treatment of tuberculosis; has also been tested for use in the treatment of leprosy.Target: Anti tuberculosisAlthough ETH and PTH are both potent drugs against M. tuberculosis (MIC = ～0.5 μg/ml) (24), they do not affect E. coli growth, even at very high concentrations (100 μg/ml), which is primarily caused by the absence of an EthA homologue in E. coli . Clinical improvement was noted in 74% of the patients treated with ethionamide and in 83% of those treated with prothionamide. Therapy was well tolerated and drug-related hepatotoxicity did not require discontinuation of therapy. The 500-mg dose of both ethionamide and prothionamide resulted in loss in Mycobacterium leprae viability more rapidly than did the 250-mg dose, and prothionamide at both dose levels was superior to the equivalent dose of ethionamide .
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备